Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.

Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.